RT Journal Article
SR Electronic
T1 Drug therapies to delay the progression of chronic kidney disease
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP 550
OP 557
DO 10.7861/clinmedicine.15-6-550
VO 15
IS 6
A1 Frank Ward
A1 John Holian
A1 Patrick T Murray
YR 2015
UL http://www.rcpjournals.org/content/15/6/550.abstract
AB Chronic kidney disease (CKD) is associated with significant morbidity and mortality, impacted not alone by progression to end-stage kidney disease, but also by the high associated incidence of cardiovascular events and related mortality. Despite our current understanding of the pathogenesis of CKD and the treatments available, the reported incidence of CKD continues to rise worldwide, and is often referred to as the silent public healthcare epidemic. The significant cost to patient wellbeing and to the economy of managing the later stages of CKD have prompted efforts to develop interventions to delay the development and progression of this syndrome. In this article, we review established and novel agents that may aid in delaying the progression of CKD and improve patient outcomes.